Protein / target
ATP-binding cassette sub-family C member 8
Protein at a glance
Biological role
ATP-activated inward rectifier potassium channel activity
Primary system
Nervous system
Strongest disease association
hyperinsulinemic hypoglycemia, familial, 1
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
12 approved
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Regulator subunit of pancreatic ATP-sensitive potassium channel (KATP), playing a major role in the regulation of insulin release. In pancreatic cells, it forms KATP channels with KCNJ11; KCNJ11 forms the channel pore while ABCC8 is required for activation and regulation
Subcellular location
Domains and Gene Ontology detail (45)Hide
Domains & features
Gene Ontology
- Cinward rectifying potassium channel
- Cplasma membrane
- Cpotassium ion-transporting ATPase complex
- Cpresynaptic membrane
- Csarcolemma
- Csynaptic vesicle membrane
- FABC-type transporter activity
- FADP binding
- FATP binding
- FATP hydrolysis activity
- FATP-activated inward rectifier potassium channel activity
- FATPase-coupled monoatomic cation transmembrane transporter activity
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Ion channel gating
- ·ATPase-coupled monoatomic cation transmembrane transporter activity
- ·potassium ion transmembrane transport
Synaptic signalling
- ·presynaptic membrane
Cell adhesion
- ·positive regulation of tight junction disassembly
View underlying pathways (3)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Sulfonylurea receptor 1, Kir6.2 blocker
Appears in clinical studies involving type 2 diabetes mellitus, diabetes mellitus, Stroke, coronary artery disorder
Sulfonylurea receptor 1, Kir6.2 blocker
Appears in clinical studies involving type 2 diabetes mellitus, diabetes mellitus, type 2 diabetes mellitus, coronary artery disorder
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 467 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 12 total
type 2 diabetes mellitus · diabetes mellitus · type 2 diabetes mellitus
type 2 diabetes mellitus · diabetes mellitus · coronary artery disorder
type 2 diabetes mellitus · diabetes mellitus · type 2 diabetes mellitus
diabetes mellitus
diabetes mellitus · type 2 diabetes mellitus · type 2 diabetes mellitus
diabetes mellitus · coronary artery disorder · type 2 diabetes mellitus
type 2 diabetes mellitus · diabetes mellitus
type 2 diabetes mellitus · type 2 diabetes mellitus
diabetes mellitus · type 2 diabetes mellitus · type 2 diabetes mellitus
type 2 diabetes mellitus · diabetes mellitus · type 2 diabetes mellitus
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Label change
Label change: GLYBURIDE AND METFORMIN HYDROCHLORIDE (ANDA206748)
- Label change
Label change: GLYBURIDE AND METFORMIN HYDROCHLORIDE (ANDA206748)
- New publicationPharmacological Inhibitors of the NLRP3 Inflammasome.
- Regulatory approval
Approval: Amglidia (EMA)
- Regulatory approval
Approval: GLYBURIDE AND METFORMIN HYDROCHLORIDE (ANDA206748)
- New publicationGlyburide in Women With Mild Gestational Diabetes: A Randomized Controlled Trial.
- New publicationEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
- New publicationEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.